A-Alpha Awarded Additional $14.5M from the DOD to Accelerate Antibody Discovery and Optimization for Likely Biothreats
We are excited to share that A-Alpha Bio has been awarded an additional $14.5M from the Department of Defense (DOD) to enable machine learning models that rapidly predict treatments against possible biological threats.
Funding from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) will expand our partnership with Lawrence Livermore National Laboratory (LLNL) in support of the Generative Unconstrained Intelligent Drug Engineering (GUIDE) program. This announcement follows two years of successful collaboration between A-Alpha and LLNL – beginning with coronaviruses and expanding to multiple undisclosed pathogen families of concern – in which A-Alpha’s AlphaSeq data has been used to train ML models that predict antibody-antigen binding. We look forward to continuing the partnership with increased scope!
To learn more, see today’s press release here.
Additional coverage: